Tumor mutations predict HER2-targeted therapy resistance in primary HER2-positive breast cancer

Abstract The presented study investigated the relevance of mutations in 17 cancer genes and response to neoadjuvant chemotherapy in two clinical cohorts of HER2+ breast cancer. 364 samples from HER2+ tumors of the neoadjuvant studies GeparTrio (no anti-HER2 treatment, n = 71) and GeparSepto (dual HE...

Full description

Bibliographic Details

Published in:	npj Breast Cancer
Main Authors:	Marion T. Van Mackelenbergh, Nicole Pfarr, Karsten Weber, Michael Untch, Christine Solbach, Andreas Schneeweiss, Paul Jank, Jens Blohmer, Denise Treue, Sabine Schmatloch, Annika Lehmann, Claus Hanusch, Theresa Link, Christine Sers, Vesna Bjelic-Radisic, Michael Hummel, Jens Huober, Wolfgang D. Schmitt, Peter A. Fasching, Bahriye Aktas, Kerstin Rhiem, Mattea Reinisch, Valentina Nekljudova, Carsten Denkert, Sibylle Loibl
Format:	Article
Language:	English
Published:	Nature Portfolio 2026-04-01
Online Access:	https://doi.org/10.1038/s41523-026-00948-7